CN117440810A - 抗肿瘤剂 - Google Patents

抗肿瘤剂 Download PDF

Info

Publication number
CN117440810A
CN117440810A CN202280036238.2A CN202280036238A CN117440810A CN 117440810 A CN117440810 A CN 117440810A CN 202280036238 A CN202280036238 A CN 202280036238A CN 117440810 A CN117440810 A CN 117440810A
Authority
CN
China
Prior art keywords
cancer
topotecan
liposome
surface area
body surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036238.2A
Other languages
English (en)
Chinese (zh)
Inventor
下山晋
铃木庆子
森干永
松本健
中山慎司
诸桥康史
木村俊文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN117440810A publication Critical patent/CN117440810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280036238.2A 2021-05-24 2022-05-23 抗肿瘤剂 Pending CN117440810A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192366P 2021-05-24 2021-05-24
US63/192,366 2021-05-24
PCT/JP2022/021103 WO2022250013A1 (ja) 2021-05-24 2022-05-23 抗腫瘍剤

Publications (1)

Publication Number Publication Date
CN117440810A true CN117440810A (zh) 2024-01-23

Family

ID=84228802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036238.2A Pending CN117440810A (zh) 2021-05-24 2022-05-23 抗肿瘤剂

Country Status (6)

Country Link
US (1) US20240099975A1 (https=)
EP (1) EP4349337A4 (https=)
JP (1) JPWO2022250013A1 (https=)
CN (1) CN117440810A (https=)
TW (1) TW202313031A (https=)
WO (1) WO2022250013A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202434243A (zh) * 2022-11-21 2024-09-01 日商富士軟片股份有限公司 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679906B1 (ko) 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
JP2004501955A (ja) 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US20090285878A1 (en) 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
RU2734900C1 (ru) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
TWI837189B (zh) * 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥

Also Published As

Publication number Publication date
WO2022250013A1 (ja) 2022-12-01
JPWO2022250013A1 (https=) 2022-12-01
EP4349337A1 (en) 2024-04-10
TW202313031A (zh) 2023-04-01
US20240099975A1 (en) 2024-03-28
EP4349337A4 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US9814734B2 (en) Bufalin liposome, preparation method therefor and application thereof
KR20090023548A (ko) 암 치료
CN108136217B (zh) 用于治疗膀胱癌的制剂
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
EP4098251A1 (en) Use of mitoxantrone hydrochloride liposome for treating breast cancer
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
CN117440810A (zh) 抗肿瘤剂
MX2010009794A (es) Uso combinado de un derivado de colestanol.
CN117355301A (zh) 处置剂
HK40102143A (zh) 抗肿瘤剂
HK40101862A (zh) 处置剂
US20250268827A1 (en) Combined medicinal drug including liposome composition encompassing topotecan or salt thereof and dna damage repair inhibitor
AU2021249949B2 (en) Antitumor agent
CA3173715C (en) Anti-tumor agent comprising a liposome encompassing gemcitabine, and uses thereof
CN102716085B (zh) 一种盐酸托泊替康脂质体注射剂
ES2992990T3 (en) Antitumor agent
HK40122907A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
OA17078A (en) New pediatric uses of cabazitaxel.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102143

Country of ref document: HK